Galectin Therapeutics adds two directors to board
This article was originally published in Scrip
Galectin Therapeutics has appointed Kevin Freeman and John Mauldin as directors on its board, bringing the total number of board members to 11. Mr Freeman is currently president of Cross Consulting Services and chief investment officer of Capitalist Publishing. Mr Mauldin is currently president of Millenium Wave Advisors.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.